Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|December 22, 2022

Determining Cisplatin Eligibility for Patients with MIBC

Author(s)Karim Chamie, MD

Dr Chamie explains how cisplatin eligibility is defined in patients with MIBC and how many patients in his practice receive neoadjuvant cisplatin therapy.

Episodes in this series

EP. 1 Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP. 1 Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP. 2 Determining Cisplatin Eligibility for Patients with MIBC

EP. 2 Determining Cisplatin Eligibility for Patients with MIBC

EP. 3 Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP. 3 Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP. 4 Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP. 4 Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP. 5 Case 2 Presentation: A 77-Year-Old Man With MIBC

EP. 5 Case 2 Presentation: A 77-Year-Old Man With MIBC

EP. 6 Unmet Needs and Clinical Challenges in the Management of MIBC

EP. 6 Unmet Needs and Clinical Challenges in the Management of MIBC

EP. 7 Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP. 7 Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP. 8 Clinical Pearls for Community Urologists Treating Patients with MIBC

EP. 8 Clinical Pearls for Community Urologists Treating Patients with MIBC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Trial assesses patient experience with at-home BCG treatment

ByTimothy D. Lyon, MD

December 4th 2025

Qualitative data show high usability of gemcitabine intravesical system

ByBenjamin P. Saylor,Hannah Clarke

December 4th 2025

TROP2 ADC demonstrates promising antitumor activity in urothelial carcinoma

ByHannah Clarke

December 2nd 2025

Félix Guerrero-Ramos, MD, highlights key takeaways from POTOMAC trial

ByFélix Guerrero-Ramos, MD, PhD, FEBU

December 1st 2025

FDA updates in urology: November 2025

ByHannah Clarke

December 1st 2025

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Surabhi Amar, MD, MHA, MBBS; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures

Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC

Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study

BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC

Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer

© 2025 MJH Life Sciences^®

All rights reserved.